Apogee Therapeutics Announces $300 Mln Public Offering

Apogee Therapeutics has commenced a public offering of $300 million of common stock. The raise will provide up to $300M in gross proceeds to fund clinical development and operations but will dilute existing shareholders. Expect near-term idiosyncratic downward pressure on the equity; the event is unlikely to affect the broader biotech sector.

Analysis

Apogee Therapeutics has commenced a public offering of $300 million of common stock. The raise will provide up to $300M in gross proceeds to fund clinical development and operations but will dilute existing shareholders. Expect near-term idiosyncratic downward pressure on the equity; the event is unlikely to affect the broader biotech sector.